A growing number of people arrive in my office holding a lab report they did not fully understand before they opened it. Somewhere on the page is a line that reads p-tau217, a number, and a flag: abnormal, elevated, or consistent with amyloid pathology.
They have usually already searched the term. What they found was either a technical paper written for researchers or a page that jumped straight to Alzheimer’s dementia. Neither answers the question they actually have, which is simpler and more urgent: What does this mean for me?
This article is the answer I give in consultation.
The Short Answer
A positive p-tau217 blood test means that the biological process associated with Alzheimer’s disease — the accumulation of amyloid plaques in the brain — is likely already underway. It is a statement about your biology, not about your diagnosis.
It does not mean you have dementia. It does not mean you will develop dementia. And on its own, without the context of your symptoms, your age, your other testing, and which assay was run, it is not sufficient to diagnose Alzheimer’s disease.
What it does mean is that you now have information most people never get: a signal, potentially decades early, during the window when intervention has the most leverage.
What p-tau217 Actually Measures
Tau is a protein that stabilizes the internal scaffolding of neurons. In Alzheimer’s disease, tau becomes abnormally phosphorylated — chemically tagged — at specific sites along the protein. Position 217 is one of those sites, and it has turned out to be unusually informative.
Here is the part that surprises most patients: although p-tau217 is a tau protein, it behaves primarily as a marker of amyloid pathology. It begins rising early in the disease process, closely tracking the point at which amyloid plaques start to accumulate — which is typically 15 to 20 years before any cognitive symptom appears.
That early rise is precisely what makes it valuable for prevention, and also what makes it so easy to misinterpret. A test that turns positive two decades before symptoms is, by design, going to be positive in a great many people who feel completely fine.
For a broader overview of how p-tau217 compares to amyloid ratios, GFAP, and neurofilament light, see Blood Tests for Alzheimer’s Risk: What’s Available Now and What They Mean.
How Accurate Is the p-tau217 Blood Test?
Remarkably accurate, by the standards of anything we have had before.
In specialty settings, high-performing p-tau217 assays identify amyloid pathology with accuracy in the range of 90 percent or better when compared against amyloid PET imaging or cerebrospinal fluid analysis — the two reference standards that previously required either several thousand dollars or a lumbar puncture.
The comparison that made the field take notice came from a large primary care study published in JAMA in 2024. Clinicians evaluating cognitive complaints with standard workup — history, examination, cognitive screening — reached the correct diagnosis roughly 61 percent of the time in primary care and 73 percent of the time in specialty care. A blood biomarker panel built on p-tau217 reached roughly 90 percent.
In 2025, the FDA cleared the first blood-based test for Alzheimer’s diagnosis: a plasma p-tau217 to beta-amyloid 1-42 ratio, authorized for adults aged 55 and older who are already being evaluated for cognitive symptoms. That last clause matters enormously, and I will come back to it.
The Three Result Zones: Positive, Borderline, and Negative
Most patients assume a biomarker test returns a yes or a no. Most modern p-tau217 tests actually return one of three answers, because a two-cutoff design produces better clinical decisions than a single line in the sand.
High probability (positive)
Your result sits above the upper cutoff. Amyloid pathology is very likely present — in most validated assays, on the order of 90 to 95 percent likely. If you have cognitive symptoms, this substantially raises the probability that Alzheimer’s disease is the cause of them. If you have no symptoms, it indicates preclinical Alzheimer’s biology rather than Alzheimer’s dementia. Those are genuinely different things.
Intermediate (borderline or indeterminate)
Your result falls between the two cutoffs. Depending on the assay and the population, somewhere between 10 and 20 percent of results land here. This is not a diagnostic failure — it is the test honestly reporting that it cannot resolve your case.
A borderline p-tau217 is the single most common reason people come to me confused, often because they were told “it’s slightly elevated” without being told that the slight elevation is, statistically, uninformative on its own. An intermediate result is an instruction to gather more information, not a partial diagnosis.
Low probability (negative)
Your result sits below the lower cutoff. This is the most decisively useful result of the three, because these tests have a high negative predictive value. A clearly negative p-tau217 is strong evidence that Alzheimer’s pathology is not driving your symptoms — which means the real cause is something else, and quite possibly something treatable.
In my practice, a negative result in a symptomatic patient reframes the entire evaluation toward sleep apnea, thyroid disease, B12 deficiency, medication side effects, depression, vascular contributions, or perimenopause. Several of those are reversible. A negative test is not the end of the workup; it is the redirection of it.
Why Your Symptoms Change the Interpretation
The same number on the same lab report means different things in different people. This is not hedging — it is how diagnostic testing works, and it is the concept most often lost when a test is ordered outside of a clinical conversation.
Every test result is interpreted against pre-test probability: how likely the condition was before the test was run. A positive p-tau217 in a 74-year-old with two years of progressive memory decline and a family history is close to confirmatory. The identical value in a 52-year-old with normal cognition, who ordered the panel out of curiosity, carries a meaningfully higher chance of being a false positive and a much longer and less certain timeline even if it is true.
This is why the Alzheimer’s Association’s 2025 clinical practice guideline on blood biomarkers recommends these tests for patients who are already being evaluated for cognitive impairment, and specifically advises against routine use in people with normal cognition outside of a research setting.
I will be direct about where I stand, because patients ask. I think that guidance is correct as a population-level default and too blunt as an individual rule. There is a real difference between screening the general public and testing a 55-year-old with two APOE4 alleles, a strong family history, and a specific plan for what to do with the answer. But the guideline is right about the thing that matters: a biomarker ordered without a plan for the result generates anxiety, not prevention.
If you are weighing whether to test at all, the more useful question is not “can I get this test” but “what would I do differently with each of the three possible answers.”
Which Test Did You Get? The Platform Matters
Not all p-tau217 tests are the same, and this is a frequent source of confusion.
Different laboratories run different assays on different analytic platforms, each with its own units, its own reference range, and its own validated cutoffs. Some report a raw p-tau217 concentration. Others report a ratio, combining p-tau217 with amyloid beta 42 or 40. Others report a composite probability score derived from several analytes.
The practical consequences:
- You cannot compare a number from one lab to a number from another. A value of 0.5 on one platform and 0.5 on another may have nothing to do with each other.
- You cannot track change over time across platforms. If you are going to repeat testing, repeat it on the same assay at the same lab.
- A result printed without its reference interval is not interpretable. If your report does not show the cutoffs used, request the full report from the laboratory.
When a patient brings me an outside result, the first thing I do is identify the platform. It is not a formality. It changes what the number means.
What Can Cause a Falsely Elevated p-tau217?
Several factors influence plasma biomarker concentrations independently of what is happening in the brain. These are worth checking before accepting a positive result at face value:
- Reduced kidney function. This is the big one. Plasma p-tau217 is cleared in part by the kidneys, and a reduced eGFR — particularly below 60 — can raise measured levels without any change in brain pathology. If your result is positive and your kidney function has never been checked, check it.
- Body mass. Higher body mass index is associated with lower measured concentrations through plasma volume dilution, which can push a truly positive result down toward the borderline zone.
- Age. Levels drift upward with age even in people who never develop Alzheimer’s disease. Age-adjusted interpretation matters, especially past 75.
- Sample handling. These assays are sensitive to pre-analytic conditions — time to centrifugation, tube type, freeze-thaw cycles. A result drawn at a facility unfamiliar with the protocol deserves more skepticism.
- Other neurological conditions. Certain conditions affecting the brain can raise tau markers to a degree, though generally with a different overall biomarker pattern.
None of these invalidate the technology. They are the ordinary reasons a single laboratory value should never be read in isolation.
What Happens Next After a Positive Result
A positive p-tau217 is the beginning of an evaluation, not the conclusion of one. Here is the sequence I follow.
1. Establish whether cognition is actually normal
Not a five-minute screening test — formal cognitive assessment sensitive enough to detect subtle change in a high-functioning person. Brief screens like the MoCA were built to detect impairment, and they routinely miss early changes in people with high cognitive reserve. Many patients who describe themselves as “fine” turn out to have a measurable change, and many who are certain something is wrong turn out to be objectively intact. You cannot interpret the biomarker without knowing which of those you are.
2. Confirm the biology if the result will drive a major decision
If a positive blood test is going to lead to a significant decision — treatment, a clinical trial, a major life or financial plan — it is reasonable to confirm with a second-line test: amyloid PET imaging or cerebrospinal fluid analysis. For borderline results, confirmation is not optional; it is the entire point.
3. Rule out what else could be contributing
Amyloid pathology and a second treatable problem coexist more often than people assume. Sleep apnea, thyroid dysfunction, B12 and folate status, medication burden with anticholinergic load, depression, alcohol, and cerebrovascular disease all warrant evaluation. Finding amyloid does not mean you stop looking.
4. Get brain imaging
An MRI with volumetric analysis establishes hippocampal volume against age-matched norms, identifies vascular contributions, and rules out structural causes. It also creates a baseline to measure against later. If your report mentions white matter changes, see My MRI Shows White Matter Changes. Does That Mean Dementia?
5. Know your APOE status
APOE genotype changes the expected trajectory, informs the intensity of prevention, and is medically necessary before any anti-amyloid therapy because it substantially changes the risk profile of those drugs. See What Is APOE4, and What Does It Actually Mean for Your Brain? and, if you already know you carry it, I Have APOE4 but No Symptoms. What Should I Do Next?
6. Build the actual prevention plan
This is the step that justifies having tested. Blood pressure, insulin sensitivity, sleep architecture and sleep apnea, aerobic and resistance training, hearing, lipids, alcohol — the modifiable factors that account for a substantial share of dementia risk at the population level, applied with far more intensity than a general wellness recommendation. See The 40%: What Modifiable Risk Factors Mean for Dementia Prevention.
7. Set a follow-up interval
Trajectory is more informative than any single value. Repeat cognitive testing and biomarker measurement on a defined schedule — typically annually — on the same platform.
What a Positive Result Does Not Mean
It does not mean you have Alzheimer’s dementia. Dementia is defined by cognitive impairment severe enough to interfere with independent daily function. A biomarker cannot establish that. Only clinical assessment can.
It does not mean decline is imminent or inevitable. Among cognitively normal people with amyloid pathology, a substantial fraction — commonly estimated around a third over roughly a decade, and heavily dependent on age — progress to mild cognitive impairment. Many do not progress within their lifetime. Older individuals with amyloid pathology are statistically more likely to die with it than from it.
It does not unlock treatment if you have no symptoms. The approved anti-amyloid antibody therapies, lecanemab and donanemab, are indicated for mild cognitive impairment or mild dementia due to Alzheimer’s disease. A positive biomarker with normal cognition does not currently meet criteria. Whether treating at the preclinical stage helps is precisely the question that ongoing prevention trials are designed to answer.
It does not mean nothing can be done. This is the belief I most want to dislodge. The interval between biomarker positivity and symptom onset is long, and it is the interval in which risk factor modification has the greatest plausible effect. A positive result in a person with normal cognition is not a verdict — it is a head start, and it is the only kind of head start this disease offers.
Common Questions
Does a positive p-tau217 test mean I definitely have Alzheimer’s disease?
No. It indicates that amyloid pathology is likely present. Under the current biological framework, abnormal biomarkers in a person without symptoms are described as preclinical Alzheimer’s disease — a biological state, not a clinical diagnosis of dementia. Many people in this state never develop dementia.
What is a normal p-tau217 level?
There is no universal normal value. Each assay has its own units and its own validated cutoffs, and results from different laboratories cannot be compared directly. Interpret your number only against the reference interval printed on your own report.
What does a borderline or intermediate p-tau217 mean?
It means the test could not resolve your amyloid status. Roughly 10 to 20 percent of results fall in this zone. It should prompt confirmatory testing — amyloid PET or cerebrospinal fluid analysis — rather than being treated as a mild positive.
Can a positive p-tau217 result be wrong?
Yes. Reduced kidney function is the most common cause of a falsely elevated result. Body mass, advanced age, sample handling, and other neurological conditions can also affect the measurement. A single value should never be interpreted in isolation.
Should I get a p-tau217 test if my memory is normal?
Current guidelines recommend these tests for people being evaluated for cognitive symptoms and advise against routine screening of people with normal cognition. Testing an asymptomatic person can be reasonable when there is elevated risk — APOE4, strong family history — and a concrete plan for acting on each possible result. Testing without such a plan tends to produce anxiety rather than prevention.
Is p-tau217 covered by insurance?
Coverage varies by payer, by indication, and by whether the specific assay has FDA clearance or is offered as a laboratory-developed test. Testing in the context of a cognitive evaluation is more likely to be covered than testing in an asymptomatic person. Confirm with your carrier and the laboratory before the draw.
How often should p-tau217 be repeated?
When monitoring is appropriate, annually is typical — always on the same assay at the same laboratory, because the trajectory is what carries information and cross-platform values are not comparable.
The Bottom Line
A positive p-tau217 is a meaningful result that deserves a careful response rather than an alarmed one. It tells you that a process is underway. It does not tell you when, or whether, that process will affect your life.
The patients who do best with this information are the ones who treat it as actionable rather than final: they confirm the finding, get a complete evaluation, identify their own modifiable risks precisely, and start working on them while there is still a long runway. The ones I worry about are those who either dismiss the result entirely or let it become a source of dread that displaces action.
You have a number and a window of time. The number is not the important part.
Dr. Nadir Bilici is a double board-certified neurologist and lifestyle medicine physician specializing in preventive neurology, Alzheimer’s prevention, and cognitive risk assessment. He sees patients via telehealth nationwide and in person in New York City.
This article is for educational purposes and does not constitute medical advice. Interpretation of any laboratory result requires evaluation by a qualified clinician who knows your history.
Published August 2026 · Medically reviewed by Nadir Bilici, MD, DipIBLM. See our editorial policy.